In winning the competition, Player 831 hopes to fund critical research, drug development, clinical trials, and resources for ...

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...

The "Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application Training Course" conference has been added to ResearchAndMarkets.com's offering. The Common ...

Reviewers have tested some of the products below and may have received some products from the manufacturers for free. All opinions are the reviewers’ own. These full-spectrum gummies are ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Jan 21 (Reuters) - The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's (JNJ.N), opens new tab nasal spray, Spravato, to allow it to be used as a standalone treatment ...

Jan. 21, 2025 -- The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed. The drug ...

The U.S. Food and Drug Administration has banned the use of red dye No. 3 in foods, more than three decades after researchers discovered its link to cancer in rodents and to worsened attention deficit ...

GSK says Nucala is the only drug in the new interleukin-5 inhibitor class to be approved in Europe in a once-monthly, self-administered format, adding that studies show 96% of patients prefer self ...